Effect of Sequential Treatment with Bisphosphonates After Teriparatide in Ovariectomized Rats: A Direct Comparison Between Risedronate and Alendronate

Yano, Tetsuo; Yamada, Mei; Inoue, Daisuke

doi:10.1007/s00223-017-0263-6

Cited by 5 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RIS has previously been reported to display a significantly greater potency for fracture prevention in patients with osteoporosis than ALN in the first year of therapy ( Silverman et al, 2007 ). We also reported that RIS might exhibit better effects on the bone quality compared with ALN in rat models ( Yano et al, 2014 ; Yano et al, 2017 ). However, the mechanisms of the distinct effects of each BP remain to be fully understood.…”

Section: Introductionmentioning

confidence: 65%

Effects of risedronate, alendronate, and minodronate alone or in combination with eldecalcitol on bone mineral density, quality, and strength in ovariectomized rats

et al. 2021

Self Cite

View full text Add to dashboard Cite

Combination therapy of active vitamin D 3 with some bisphosphonates (BPs) has been reported to be clinically beneficial. However, combination therapy of eldecalcitol (ELD) with BP has to date not been validated as to whether it is beneficial in the clinical setting. Preclinical studies suggested that simultaneous treatment with ELD and some BPs is more effective than monotherapy. However, the relative potency of various BPs, when used in combination with ELD, is completely unknown. In this study, we examined and compared the effects of risedronate (RIS), alendronate (ALN), and minodronate (MIN) alone or in combination with ELD on bone mass, microarchitecture, strength, and material properties in ovariectomized Sprague-Dawley rats aged 13 weeks. RIS, ALN, MIN, and ELD were administered five times weekly for 16 weeks. Micro-computed tomography analysis, compression test, and Fourier transform infrared (FTIR) imaging analysis were performed 16 weeks after treatment initiation. Trabecular and cortical bone mineral density (BMD) in the fourth lumbar vertebra (L4) significantly increased in the RIS + ELD, ALN + ELD, and MIN + ELD groups compared with the vehicle group. Moreover, the bone microarchitecture of L4 in all the BP + ELD groups also significantly improved. On mechanical testing of L4, the maximum load was significantly increased in the RIS + ELD and ALN + ELD groups. FTIR analysis revealed that the mineral-to-collagen ratio of trabecular bone in L3 of all the BP + ELD groups was significantly increased compared with the vehicle group. By contrast, the carbonate-to-phosphate ratio, a parameter of mineral immaturity, was significantly decreased in the RIS + ELD and ALN + ELD groups. BP + ELD improved the BMD and structural properties of the bone to a similar extent. RIS + ELD and ALN + ELD also improved bone strength. Furthermore, treatment with BP + ELD improved the bone material. These results suggest that the combination therapy of BP and ELD is beneficial and warrants further clinical trials.

show abstract

Section: Introductionmentioning

confidence: 65%

Effects of risedronate, alendronate, and minodronate alone or in combination with eldecalcitol on bone mineral density, quality, and strength in ovariectomized rats

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The results of the current study showed an increase in BMD in vertebral trabecular bone with monotherapy of ZA, AL, and RI (27.5% for ZA, 21.3% for RI and 17.7 % for AL). Yano et al (19) reported that RI may have a greater impact on improving bone quality than AL, despite the less prominent effect on BMD. Most studies reported ZA as the most potent drug of bisphosphonates, which significantly increase the BMD and reduce the risk of fractures in comparison to other bisphos-phonates (20).…”

Section: Discussionmentioning

confidence: 99%

The Effect of Systemic Delivery of Bisphosphonates on Trabecular and Cortical Bone Mass of Ovariectomized Rats

Shahrezaee

Oryan

et al. 2018

Ann Mil Health Sci Res

View full text Add to dashboard Cite

Background: Bisphosphonates are one of the most important drug families, which inhibit osteoclast-mediated bone loss due to osteoporosis and other disorders. However, the impact of different members of this family of drugs on the various cortical and trabecular bone mineral density wasn't investigated. Objectives: In this study the therapeutic effects of bisphosphonates in Ovariectomized (OVX) female rats was assessed, for eight weeks, and these effects were compared on trabecular and cortical bones. Methods: Thirty adult female rats (225 + 25 g) were divided to five equal groups [Sham, the untreated OVX rats (negative control), and the OVX rats treated with zoledronic acid, alendronate, and risedronate]. The effectiveness of these treatments after eight weeks was comprehensively evaluated by in vivo and in vitro analysis. Results: Systemic delivery of zoledronic acid, alendronate, and risedronate had statistically significant effects on serum parameters in comparison to the untreated OVX animals. Moreover, administration of zoledronic acid, alendronate, and risedronate increased expression of osteogenic genes (OCN, ALP, and Col1), bone mineral density (BMD), and biomechanical performance of the OVX-induced osteoporotic bones in comparison with the untreated OVX rats (P < 0.05). However, different analyses showed that trabecular BMD significantly increased in zoledronic acid-and risedronate-treated animals in comparison to those of the alendronatetreated group (P < 0.05). Conclusions: It was concluded that zoledronic acid, alendronate, and risedronate sufficiently improved OVX-induced osteopenia. Moreover, it was found out that zoledronic acid and risedronate considerably improved the regeneration of trabecular bones in comparison to the alendronate.

show abstract

“…After micro-CT scan, the right side femur was tested for bone strength by three-point bending test [ 23 ]. The biomechanical testing was done using ElectroPuls E10000 Linear-Torsion all-electric dynamic test instrument (INSTRON, MA, USA).…”

Section: Methodsmentioning

confidence: 99%

Alamandine attenuates ovariectomy-induced osteoporosis by promoting osteogenic differentiation via AMPK/eNOS axis

Luo,

Yao,

Sun

et al. 2024

BMC Musculoskelet Disord

View full text Add to dashboard Cite

Background Alamandine is a newly characterized peptide of renin angiotensin system. Our study aims to investigate the osteo-preservative effects of alamandine, explore underlying mechanism and bring a potential preventive strategy for postmenopausal osteoporosis in the future. Methods An ovariectomy (OVX)-induced rat osteoporosis model was established for in vivo experiments. Micro-computed tomography and three-point bending test were used to evaluate bone strength. Histological femur slices were processed for immunohistochemistry (IHC). Bone turnover markers and nitric oxide (NO) concentrations in serum were determined with enzyme-linked immunosorbent assay (ELISA). The mouse embryo osteoblast precursor (MC3T3-E1) cells were used for in vitro experiments. The cell viability was analysed with a Cell Counting Kit‑8. We performed Alizarin Red S staining and alkaline phosphatase (ALP) activity assay to observe the differentiation status of osteoblasts. Western blotting was adopted to detect the expression of osteogenesis related proteins and AMP-activated protein kinase/endothelial nitric oxide synthase (AMPK/eNOS) in osteoblasts. DAF-FM diacetate was used for semi-quantitation of intracellular NO. Results In OVX rats, alamandine alleviated osteoporosis and maintained bone strength. The IHC showed alamandine increased osteocalcin and collagen type I α1 (COL1A1) expression. The ELISA revealed alamandine decreased bone turnover markers and restored NO level in serum. In MC3T3-E1 cells, alamandine promoted osteogenic differentiation. Western blotting demonstrated that alamandine upregulated the expression of osteopontin, Runt-related transcription factor 2 and COL1A1. The intracellular NO was also raised by alamandine. Additionally, the activation of AMPK/eNOS axis mediated the effects of alamandine on MC3T3-E1 cells and bone tissue. PD123319 and dorsomorphin could repress the regulating effect of alamandine on bone metabolism. Conclusion Alamandine attenuates ovariectomy-induced osteoporosis by promoting osteogenic differentiation via AMPK/eNOS axis.

show abstract

Effect of Sequential Treatment with Bisphosphonates After Teriparatide in Ovariectomized Rats: A Direct Comparison Between Risedronate and Alendronate

Cited by 5 publications

References 40 publications

Effects of risedronate, alendronate, and minodronate alone or in combination with eldecalcitol on bone mineral density, quality, and strength in ovariectomized rats

Effects of risedronate, alendronate, and minodronate alone or in combination with eldecalcitol on bone mineral density, quality, and strength in ovariectomized rats

The Effect of Systemic Delivery of Bisphosphonates on Trabecular and Cortical Bone Mass of Ovariectomized Rats

Alamandine attenuates ovariectomy-induced osteoporosis by promoting osteogenic differentiation via AMPK/eNOS axis

Contact Info

Product

Resources

About